Tacoma General Allenmore Hospital
- Type
- Teaching hospital
- Where
- Tacoma, WA
- Medicare CCN
- 500129
- Received
- $3,670,041 in 433 records, 2020 ($71,205 general, $3,598,836 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2020 | General payment | 14 | $71,205 |
| 2020 | Research payment | 419 | $3,598,836 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 419 | $3,598,836 |
| Honoraria | 1 | $38,721 |
| Gift | 6 | $26,958 |
| Space rental or facility fees (teaching hospital only) | 2 | $3,000 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 3 | $1,715 |
| Education | 2 | $809 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2020-12-31 | Allergan, Inc. | $33,002 | Research payment | In-kind items and services | A multicenter, randomized, double-blind, dose-conversion study to evaluate the safety and efficacy of HRT w Armour Thyro | 2020 | |
| 2020-12-31 | Allergan, Inc. | $13,698 | Research payment | In-kind items and services | A multicenter, randomized, double-blind, dose-conversion study to evaluate the safety and efficacy of HRT w Armour Thyro | 2020 | |
| 2020-12-31 | Allergan, Inc. | $1,740 | Research payment | In-kind items and services | A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamoreli | 2020 | |
| 2020-12-31 | Allergan, Inc. | $1,080 | Research payment | In-kind items and services | Clinical Trial (LIN-MD-64: Ped FC Trial 6-17 Ph3) | 2020 | |
| 2020-12-31 | Allergan, Inc. | $406 | Research payment | In-kind items and services | BOTOX COSMETIC Biological | A Study Evaluating the Efficacy and Safety of BOTOX Intravesical Instillation in Patients with Overactive Bladder and Ur | 2020 |
| 2020-12-31 | Masimo Corporation | $27 | Education | In-kind items and services | rainbow Acoustic Monitoring Device, Devices | 2020 | |
| 2020-12-31 | Zimmer Biomet Holdings, Inc. | $0 | Gift | In-kind items and services | Device, Zimmer Biomet Instruments and Implants | 2020 | |
| 2020-12-30 | ABBVIE INC. | $8,169 | Research payment | Cash or cash equivalent | LUPRON DEPOT Drug, ENDOCRINOLOGY | M16-904 | 2020 |
| 2020-12-29 | Merck Sharp & Dohme LLC | $2,056 | Research payment | Cash or cash equivalent | V114 Biological, VACCINE | A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerabilit | 2020 |
| 2020-12-28 | Janssen Research & Development, LLC | $2,164 | Research payment | Cash or cash equivalent | A long-term, multicenter, single-arm, open-label extension of the SERENADE study, to assess the safety and efficacy of m | 2020 | |
| 2020-12-23 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $4,181 | Research payment | Cash or cash equivalent | LifeVest Device, Electromedical and Electrotherapeutic Apparatus | BMAD | 2020 |
| 2020-12-23 | Gilead Sciences, Inc. | $2,698 | Research payment | Cash or cash equivalent | A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhib | 2020 | |
| 2020-12-23 | ABBVIE INC. | $2,550 | Research payment | Cash or cash equivalent | LUPRON DEPOT Drug, ENDOCRINOLOGY | M16-904 | 2020 |
| 2020-12-21 | Artivion, Inc. | $2,384 | Research payment | Cash or cash equivalent | On-X Device, Cardiology and Vascular Diseases | On-X aortic prosthetic heart valve: Low dose warfarin post approval clinical registry | 2020 |
| 2020-12-17 | PFIZER INC. | $2,707 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIA | 2020 | |
| 2020-12-16 | Merck Sharp & Dohme LLC | $6,533 | Research payment | Cash or cash equivalent | MK-8591A Drug, INFECTIOUS DISEASE | A Phase 3, Randomized, Active-Controlled, Double-blind Clinical Study to Evaluate a Switch to Doravirine,Islatravir DOR, | 2020 |
| 2020-12-16 | Merck Sharp & Dohme LLC | $175 | Research payment | Cash or cash equivalent | V160 Biological, VACCINE | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy | 2020 |
| 2020-12-16 | Gilead Sciences, Inc. | $104 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafena | 2020 |
| 2020-12-15 | Allergan, Inc. | $3,348 | Research payment | Cash or cash equivalent | A multicenter, randomized, double-blind, dose-conversion study to evaluate the safety and efficacy of HRT w Armour Thyro | 2020 | |
| 2020-12-15 | Allergan, Inc. | $1,116 | Research payment | Cash or cash equivalent | A multicenter, randomized, double-blind, dose-conversion study to evaluate the safety and efficacy of HRT w Armour Thyro | 2020 | |
| 2020-12-14 | Merck Sharp & Dohme LLC | $3,000 | Research payment | Cash or cash equivalent | MK-4482 Biological, INFECTIOUS DISEASE | A Phase 2,3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacok | 2020 |
| 2020-12-10 | Regeneron Pharmaceuticals, Inc. | $1,423 | Research payment | Cash or cash equivalent | PRALUENT Biological, CARDIOVASCULAR AND METABOLISM | LONG TERM SAFETY STUDY OF PRALUENT IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA OR WITH NON-FAMILIAL HYPE | 2020 |
| 2020-12-10 | Regeneron Pharmaceuticals, Inc. | $1,000 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2020 |
| 2020-12-10 | Alexion Pharmaceuticals, Inc. | $840 | Research payment | Cash or cash equivalent | Lysosomal Acid Lipase (LAL) Deficiency Registry (ALX-LALD-501) | 2020 | |
| 2020-12-10 | Alexion Pharmaceuticals, Inc. | $127 | Research payment | Cash or cash equivalent | Lysosomal Acid Lipase (LAL) Deficiency Registry (ALX-LALD-501) | 2020 | |
| 2020-12-08 | Genentech, Inc. | $128 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHII IL22FC ANTI ST2 IN SEVERE COVID 19 PNEUMONIA | 2020 |
| 2020-12-03 | PFIZER INC. | $11,750 | Research payment | Cash or cash equivalent | A PHASE 2B RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY TO ASSESS THE EFFICACY SAFETY AND T | 2020 | |
| 2020-12-02 | ABBVIE INC. | $3,965 | Research payment | Cash or cash equivalent | LUPRON DEPOT Drug, ENDOCRINOLOGY | M16-904 | 2020 |
| 2020-12-02 | ABBVIE INC. | $2,274 | Research payment | Cash or cash equivalent | HUMIRA Biological, IMMUNOLOGY | P11-292 | 2020 |
| 2020-12-01 | Merck Sharp & Dohme LLC | $6,315 | Research payment | Cash or cash equivalent | V114 Biological, VACCINE | A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerabilit | 2020 |
| 2020-12-01 | Merck Sharp & Dohme LLC | $1,419 | Research payment | Cash or cash equivalent | V114 Biological, VACCINE | A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerabilit | 2020 |
| 2020-11-30 | Genentech, Inc. | $80 | Research payment | Cash or cash equivalent | OCREVUS Biological, Immunology | ENSEMBLE | 2020 |
| 2020-11-25 | Incyte Corporation | $2,000 | Research payment | Cash or cash equivalent | A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepat | 2020 | |
| 2020-11-25 | Incyte Corporation | $1,540 | Research payment | Cash or cash equivalent | A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepat | 2020 | |
| 2020-11-25 | Incyte Corporation | $1,000 | Research payment | Cash or cash equivalent | A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepat | 2020 | |
| 2020-11-25 | Incyte Corporation | $797 | Research payment | Cash or cash equivalent | A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepat | 2020 | |
| 2020-11-23 | GENZYME CORPORATION | $9,062 | Research payment | Cash or cash equivalent | Fabry LSD Data Registry | 2020 | |
| 2020-11-23 | GENZYME CORPORATION | $2,289 | Research payment | Cash or cash equivalent | Pompe LSD Data Registry | 2020 | |
| 2020-11-23 | GENZYME CORPORATION | $903 | Research payment | Cash or cash equivalent | Fabry LSD Data Registry | 2020 | |
| 2020-11-20 | Merck Sharp & Dohme LLC | $1,171 | Research payment | Cash or cash equivalent | V160 Biological, VACCINE | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy | 2020 |
| 2020-11-19 | Merck Sharp & Dohme LLC | $3,777 | Research payment | In-kind items and services | MK-4482 Biological, INFECTIOUS DISEASE | A Phase 2,3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacok | 2020 |
| 2020-11-19 | ABBVIE INC. | $849 | Research payment | Cash or cash equivalent | LUPRON DEPOT Drug, ENDOCRINOLOGY | M16-904 | 2020 |
| 2020-11-19 | Merck Sharp & Dohme LLC | $57 | Research payment | In-kind items and services | MK-1654 Drug, INFECTIOUS DISEASE | A Double-blind, Randomized, Placebo-controlled, Single Ascending Dose Trial to Evaluate the Safety, Tolerability, and Ph | 2020 |
| 2020-11-18 | Merck Sharp & Dohme LLC | $17,864 | Research payment | Cash or cash equivalent | MK-8591A Drug, INFECTIOUS DISEASE | A Phase 3, Randomized, Active-Controlled, Double-blind Clinical Study to Evaluate a Switch to Doravirine,Islatravir DOR, | 2020 |
| 2020-11-18 | Gilead Sciences, Inc. | $2,978 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of a Fixed Dose Combination of GS-9883/ Emtricita | 2020 |
| 2020-11-18 | Gilead Sciences, Inc. | $1,904 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafena | 2020 |
| 2020-11-17 | Allergan, Inc. | $6,684 | Research payment | Cash or cash equivalent | A multicenter, randomized, double-blind, dose-conversion study to evaluate the safety and efficacy of HRT w Armour Thyro | 2020 | |
| 2020-11-17 | Genentech, Inc. | $3,255 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHII IL22FC ANTI ST2 IN SEVERE COVID 19 PNEUMONIA | 2020 |
| 2020-11-16 | Gilead Sciences, Inc. | $1,914 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | The Simple Study - Subjects with Mild to Moderate Coronavirus Infection | 2020 |
| 2020-11-16 | Merck Sharp & Dohme LLC | $1,220 | Research payment | Cash or cash equivalent | V160 Biological, VACCINE | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy | 2020 |
| 2020-11-16 | Gilead Sciences, Inc. | $1,000 | Research payment | Cash or cash equivalent | A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhib | 2020 | |
| 2020-11-13 | Janssen Research & Development, LLC | $394 | Research payment | Cash or cash equivalent | A long-term, multicenter, single-arm, open-label extension of the SERENADE study, to assess the safety and efficacy of m | 2020 | |
| 2020-11-12 | Alexion Pharmaceuticals, Inc. | $440 | Research payment | Cash or cash equivalent | Lysosomal Acid Lipase (LAL) Deficiency Registry (ALX-LALD-501) | 2020 | |
| 2020-11-11 | Novartis Gene Therapies, Inc. (fka Avexis, Inc.) | $891 | Research payment | Cash or cash equivalent | ZOLGENSMA Biological, GENE THERAPY | A Prospective, Long-Term Registry of Patients with a Diagnosis of Spinal Muscular Atrophy | 2020 |
| 2020-11-10 | Allergan, Inc. | $500 | Research payment | Cash or cash equivalent | A multicenter, randomized, double-blind, dose-conversion study to evaluate the safety and efficacy of HRT w Armour Thyro | 2020 | |
| 2020-11-09 | PFIZER INC. | $16,775 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED MULTICENTER OPENLABEL CROSSOVER STUDY ASSESSING SUBJECT PERCEPTION OF TREATMENT BURDEN WITH USE OF | 2020 | |
| 2020-11-09 | PFIZER INC. | $7,297 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED MULTICENTER OPENLABEL CROSSOVER STUDY ASSESSING SUBJECT PERCEPTION OF TREATMENT BURDEN WITH USE OF | 2020 | |
| 2020-11-09 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED MULTICENTER OPENLABEL CROSSOVER STUDY ASSESSING SUBJECT PERCEPTION OF TREATMENT BURDEN WITH USE OF | 2020 | |
| 2020-11-02 | SK Life Science, Inc. | $2,853 | Research payment | Cash or cash equivalent | Cenobamate Drug, Neurology | YKP3089C025 | 2020 |
| 2020-11-02 | PFIZER INC. | $573 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED MULTICENTER OPENLABEL CROSSOVER STUDY ASSESSING SUBJECT PERCEPTION OF TREATMENT BURDEN WITH USE OF | 2020 | |
| 2020-10-29 | Merck Sharp & Dohme LLC | $10,429 | Research payment | Cash or cash equivalent | V114 Biological, VACCINE | A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerabilit | 2020 |
| 2020-10-29 | ABBVIE INC. | $3,878 | Research payment | Cash or cash equivalent | LUPRON DEPOT Drug, ENDOCRINOLOGY | M16-904 | 2020 |
| 2020-10-29 | Merck Sharp & Dohme LLC | $2,056 | Research payment | Cash or cash equivalent | V114 Biological, VACCINE | A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerabilit | 2020 |
| 2020-10-29 | Astellas Pharma Global Development | $800 | Research payment | Cash or cash equivalent | XOSPATA Drug, ONCOLOGY | RANDOMIZED TRIAL OF GILTERITINIB VS MIDOSTAURIN IN FLT3 MUTATED ACUTE MYELOID LEUKEMIA (AML | 2020 |
| 2020-10-28 | Gilead Sciences, Inc. | $4,250 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | The Simple Study in Coronavirus, Severe Subjects | 2020 |
| 2020-10-27 | Merck Sharp & Dohme LLC | $2,564 | Research payment | In-kind items and services | MK-4482 Biological, INFECTIOUS DISEASE | A Phase 2,3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacok | 2020 |
| 2020-10-27 | Merck Sharp & Dohme LLC | $188 | Research payment | In-kind items and services | MK-1654 Drug, INFECTIOUS DISEASE | A Double-blind, Randomized, Placebo-controlled, Single Ascending Dose Trial to Evaluate the Safety, Tolerability, and Ph | 2020 |
| 2020-10-26 | Genentech, Inc. | $7,848 | Research payment | Cash or cash equivalent | OCREVUS Biological, Immunology | ENSEMBLE | 2020 |
| 2020-10-21 | Merck Sharp & Dohme LLC | $11,250 | Research payment | Cash or cash equivalent | MK-4482 Biological, INFECTIOUS DISEASE | A Phase 2,3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacok | 2020 |
| 2020-10-21 | Merck Sharp & Dohme LLC | $11,250 | Research payment | Cash or cash equivalent | MK-4482 Biological, INFECTIOUS DISEASE | A Phase 2,3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacok | 2020 |
| 2020-10-21 | Gilead Sciences, Inc. | $6,376 | Research payment | Cash or cash equivalent | A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhib | 2020 | |
| 2020-10-21 | Artivion, Inc. | $3,104 | Research payment | Cash or cash equivalent | On-X Device, Cardiology and Vascular Diseases | On-X aortic prosthetic heart valve: Low dose warfarin post approval clinical registry | 2020 |
| 2020-10-21 | Gilead Sciences, Inc. | $952 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafena | 2020 |
| 2020-10-20 | Genentech, Inc. | $750 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHII IL22FC ANTI ST2 IN SEVERE COVID 19 PNEUMONIA | 2020 |
| 2020-10-19 | SK Life Science, Inc. | $3,417 | Research payment | Cash or cash equivalent | Cenobamate Drug, Neurology | YKP3089C033 | 2020 |
| 2020-10-19 | SK Life Science, Inc. | $1,000 | Research payment | Cash or cash equivalent | Cenobamate Drug, Neurology | YKP3089C025 | 2020 |
| 2020-10-19 | Genentech, Inc. | $350 | Research payment | Cash or cash equivalent | OCREVUS Biological, Immunology | OCARINA I | 2020 |
| 2020-10-19 | Merck Sharp & Dohme LLC | $200 | Research payment | Cash or cash equivalent | V160 Biological, VACCINE | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy | 2020 |
| 2020-10-16 | Merck Sharp & Dohme LLC | $15,154 | Research payment | Cash or cash equivalent | V160 Biological, VACCINE | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy | 2020 |
| 2020-10-15 | Allergan, Inc. | $10,044 | Research payment | Cash or cash equivalent | A multicenter, randomized, double-blind, dose-conversion study to evaluate the safety and efficacy of HRT w Armour Thyro | 2020 | |
| 2020-10-15 | Allergan, Inc. | $4,310 | Research payment | Cash or cash equivalent | A multicenter, randomized, double-blind, dose-conversion study to evaluate the safety and efficacy of HRT w Armour Thyro | 2020 | |
| 2020-10-14 | Merck Sharp & Dohme LLC | $346 | Research payment | In-kind items and services | MK-4482 Biological, INFECTIOUS DISEASE | A Phase 2,3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacok | 2020 |
| 2020-10-14 | Alexion Pharmaceuticals, Inc. | $314 | Research payment | Cash or cash equivalent | Lysosomal Acid Lipase (LAL) Deficiency Registry (ALX-LALD-501) | 2020 | |
| 2020-10-13 | SANOFI PASTEUR INC. | $12,000 | Research payment | Cash or cash equivalent | VAD00001 Study of a Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers | 2020 | |
| 2020-10-08 | Regeneron Pharmaceuticals, Inc. | $2,924 | Research payment | Cash or cash equivalent | PRALUENT Biological, CARDIOVASCULAR AND METABOLISM | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFECT OF PRALUENT ON NEUROCOGNITIVE FUNCTION IN PA | 2020 |
| 2020-10-05 | Eli Lilly and Company | $11,140 | Research payment | Cash or cash equivalent | PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREA | 2020 | |
| 2020-10-05 | Eli Lilly and Company | $11,140 | Research payment | Cash or cash equivalent | A PHASE 3, 12 MONTH, OPEN LABEL STUDY OF LASMIDITAN IN PEDIATRIC PATIENTS WITH MIGRAINE PIONEER PEDS2 | 2020 | |
| 2020-10-02 | Merck Sharp & Dohme LLC | $6,125 | Research payment | Cash or cash equivalent | MK-8591A Drug, INFECTIOUS DISEASE | A Phase 3, Randomized, Active-Controlled, Double-blind Clinical Study to Evaluate a Switch to Doravirine,Islatravir DOR, | 2020 |
| 2020-10-02 | Medical Device Business Services, Inc. | $627 | Research payment | Cash or cash equivalent | Visitag Device, Cardiology | Evaluation of VISITAG SURPOINT Module with External Processing Unit (EPU) when used with the THERMOCOOL SMARTTOUCH SF an | 2020 |
| 2020-09-30 | ABBVIE INC. | $225 | Research payment | Cash or cash equivalent | LUPRON DEPOT Drug, ENDOCRINOLOGY | M16-904 | 2020 |
| 2020-09-28 | Janssen Research & Development, LLC | $11,122 | Research payment | Cash or cash equivalent | A long-term, multicenter, single-arm, open-label extension of the SERENADE study, to assess the safety and efficacy of m | 2020 | |
| 2020-09-24 | GW Research Limited | $15,000 | Research payment | Cash or cash equivalent | GWEP18060 | 2020 | |
| 2020-09-24 | F. Hoffmann-La Roche AG | $4,614 | Research payment | Cash or cash equivalent | OCREVUS Biological, Immunology | OCRELIZUMAB IN PATIENTS WITH RMS | 2020 |
| 2020-09-24 | Merck Sharp & Dohme LLC | $3,476 | Research payment | Cash or cash equivalent | V114 Biological, VACCINE | A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerabilit | 2020 |
| 2020-09-24 | Merck Sharp & Dohme LLC | $2,839 | Research payment | Cash or cash equivalent | V114 Biological, VACCINE | A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerabilit | 2020 |
| 2020-09-24 | Genentech, Inc. | $1,497 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHII IL22FC ANTI ST2 IN SEVERE COVID 19 PNEUMONIA | 2020 |
| 2020-09-23 | Gilead Sciences, Inc. | $5,498 | Research payment | Cash or cash equivalent | A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhib | 2020 | |
| 2020-09-23 | Gilead Sciences, Inc. | $1,399 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | The Simple Study in Coronavirus, Severe Subjects | 2020 |
| 2020-09-23 | Gilead Sciences, Inc. | $904 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafena | 2020 |
| 2020-09-23 | Gilead Sciences, Inc. | $888 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of a Fixed Dose Combination of GS-9883/ Emtricita | 2020 |
| 2020-09-21 | SK Life Science, Inc. | $1,074 | Research payment | Cash or cash equivalent | Cenobamate Drug, Neurology | YKP3089C033 | 2020 |
| 2020-09-18 | PFIZER INC. | $13,500 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIA | 2020 | |
| 2020-09-18 | Artivion, Inc. | $2,443 | Research payment | Cash or cash equivalent | On-X Device, Cardiology and Vascular Diseases | On-X aortic prosthetic heart valve: Low dose warfarin post approval clinical registry | 2020 |
| 2020-09-16 | Merck Sharp & Dohme LLC | $6,942 | Research payment | Cash or cash equivalent | MK-8591A Drug, INFECTIOUS DISEASE | A Phase 3, Randomized, Active-Controlled, Double-blind Clinical Study to Evaluate a Switch to Doravirine,Islatravir DOR, | 2020 |
| 2020-09-16 | Alexion Pharmaceuticals, Inc. | $1,085 | Research payment | Cash or cash equivalent | Lysosomal Acid Lipase (LAL) Deficiency Registry (ALX-LALD-501) | 2020 | |
| 2020-09-16 | ABBVIE INC. | $449 | Research payment | Cash or cash equivalent | HUMIRA Biological, IMMUNOLOGY | P11-292 | 2020 |
| 2020-09-15 | Allergan, Inc. | $16,160 | Research payment | Cash or cash equivalent | A multicenter, randomized, double-blind, dose-conversion study to evaluate the safety and efficacy of HRT w Armour Thyro | 2020 | |
| 2020-09-15 | Allergan, Inc. | $2,713 | Research payment | Cash or cash equivalent | A multicenter, randomized, double-blind, dose-conversion study to evaluate the safety and efficacy of HRT w Armour Thyro | 2020 | |
| 2020-09-14 | Merck Sharp & Dohme LLC | $20,559 | Research payment | Cash or cash equivalent | MK-8591A Drug, INFECTIOUS DISEASE | A Phase 3, Randomized, Active-Controlled, Double-blind Clinical Study to Evaluate a Switch to Doravirine,Islatravir DOR, | 2020 |
| 2020-09-14 | Gilead Sciences, Inc. | $1,500 | Research payment | Cash or cash equivalent | MOSAIC - A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Effi | 2020 | |
| 2020-09-14 | Merck Sharp & Dohme LLC | $96 | Research payment | Cash or cash equivalent | MK-7264 Drug, RESPIRATORY | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-Month Study to Evaluate the Efficacy and Safety of MK-7264 i | 2020 |
| 2020-09-10 | CSL Behring | $1,250 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-09-10 | CSL Behring | $1,000 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-09-10 | CSL Behring | $750 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-09-10 | CSL Behring | $500 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-09-08 | Genentech, Inc. | $4,226 | Research payment | Cash or cash equivalent | OCREVUS Biological, Immunology | ENSEMBLE | 2020 |
| 2020-09-08 | Genentech, Inc. | $3,360 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHII IL22FC ANTI ST2 IN SEVERE COVID 19 PNEUMONIA | 2020 |
| 2020-09-08 | Allergan, Inc. | $500 | Research payment | Cash or cash equivalent | Clinical Trial (LIN-MD-67: Ped FC Trial 2-5 Ph2) | 2020 | |
| 2020-09-04 | Medical Device Business Services, Inc. | $1,500 | Research payment | Cash or cash equivalent | Visitag Device, Cardiology | Evaluation of VISITAG SURPOINT Module with External Processing Unit (EPU) when used with the THERMOCOOL SMARTTOUCH SF an | 2020 |
| 2020-09-03 | Incyte Corporation | $4,000 | Research payment | Cash or cash equivalent | A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepat | 2020 | |
| 2020-09-03 | F. Hoffmann-La Roche AG | $2,958 | Research payment | Cash or cash equivalent | OCREVUS Biological, Immunology | OCRELIZUMAB IN PATIENTS WITH RMS | 2020 |
| 2020-09-03 | Incyte Corporation | $1,000 | Research payment | Cash or cash equivalent | A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepat | 2020 | |
| 2020-09-03 | Incyte Corporation | $1,000 | Research payment | Cash or cash equivalent | A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepat | 2020 | |
| 2020-09-03 | Sterilmed, Inc. | $658 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-09-03 | Incyte Corporation | $500 | Research payment | Cash or cash equivalent | A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepat | 2020 | |
| 2020-09-01 | Amgen Inc. | $2,129 | Research payment | Cash or cash equivalent | Repatha Biological, Cardiology | OSLER OLE | 2020 |
| 2020-09-01 | PFIZER INC. | $88 | Research payment | Cash or cash equivalent | AN OPENLABEL EXTENSION STUDY TO ASSESS THE LONGTERM SAFETY AND EFFICACY OF PF04965842 IN ADULT PATIENTS WITH MODERATETOS | 2020 | |
| 2020-08-31 | Eli Lilly and Company | $7,695 | Research payment | Cash or cash equivalent | A RANDOMIZED PHASE 2 TRIAL OF AM0010 IN COMBINATION WITH NIVOLUMAB VS. NIVOLUMAB ALONE AS SECOND-LINE THERAPY IN SUBJECT | 2020 | |
| 2020-08-31 | SK Life Science, Inc. | $204 | Research payment | Cash or cash equivalent | Cenobamate Drug, Neurology | YKP3089C033 | 2020 |
| 2020-08-28 | ABBVIE INC. | $477 | Research payment | Cash or cash equivalent | LUPRON DEPOT Drug, ENDOCRINOLOGY | M16-904 | 2020 |
| 2020-08-27 | Amgen Inc. | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Repatha Biological, Cardiology | 2020 | |
| 2020-08-26 | Merck Sharp & Dohme LLC | $125 | Research payment | Cash or cash equivalent | V160 Biological, VACCINE | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy | 2020 |
| 2020-08-25 | Merck Sharp & Dohme LLC | $1,119 | Research payment | Cash or cash equivalent | V114 Biological, VACCINE | A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with R | 2020 |
| 2020-08-24 | GENZYME CORPORATION | $2,451 | Research payment | Cash or cash equivalent | Fabry LSD Data Registry | 2020 | |
| 2020-08-24 | GENZYME CORPORATION | $516 | Research payment | Cash or cash equivalent | Gaucher LSD Data Registry | 2020 | |
| 2020-08-24 | GENZYME CORPORATION | $451 | Research payment | Cash or cash equivalent | Pompe LSD Data Registry | 2020 | |
| 2020-08-20 | Merck Sharp & Dohme LLC | $7,590 | Research payment | Cash or cash equivalent | V114 Biological, VACCINE | A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerabilit | 2020 |
| 2020-08-20 | Merck Sharp & Dohme LLC | $5,533 | Research payment | Cash or cash equivalent | V114 Biological, VACCINE | A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerabilit | 2020 |
| 2020-08-20 | Mallinckrodt Hospital Products Inc. | $4,750 | Research payment | Cash or cash equivalent | ACTHAR Biological, IMMUNOLOGY | A MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED PARALLEL GROUP, PILOT STUDY TO ASSESS THE EFFICACY AND SAFET | 2020 |
| 2020-08-20 | Regeneron Pharmaceuticals, Inc. | $2,739 | Research payment | Cash or cash equivalent | PRALUENT Biological, CARDIOVASCULAR AND METABOLISM | LONG TERM SAFETY STUDY OF PRALUENT IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA OR WITH NON-FAMILIAL HYPE | 2020 |
| 2020-08-20 | Eli Lilly and Company | $1,005 | Research payment | In-kind items and services | THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SU | 2020 | |
| 2020-08-19 | Gilead Sciences, Inc. | $4,149 | Research payment | Cash or cash equivalent | A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhib | 2020 | |
| 2020-08-19 | Gilead Sciences, Inc. | $1,808 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafena | 2020 |
| 2020-08-19 | Gilead Sciences, Inc. | $888 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of a Fixed Dose Combination of GS-9883/ Emtricita | 2020 |
| 2020-08-18 | Novartis Gene Therapies, Inc. (fka Avexis, Inc.) | $3,000 | Research payment | Cash or cash equivalent | ZOLGENSMA Biological, GENE THERAPY | A Prospective, Long-Term Registry of Patients with a Diagnosis of Spinal Muscular Atrophy | 2020 |
| 2020-08-18 | Artivion, Inc. | $1,156 | Research payment | Cash or cash equivalent | On-X Device, Cardiology and Vascular Diseases | On-X aortic prosthetic heart valve: Low dose warfarin post approval clinical registry | 2020 |
| 2020-08-17 | Eli Lilly and Company | $680,277 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP PHASE 3 STUDY OF BARICITINIB IN PATIENTS WITH COVID 19 IN | 2020 | |
| 2020-08-17 | Merck Sharp & Dohme LLC | $36,978 | Research payment | Cash or cash equivalent | MK-8591A Drug, INFECTIOUS DISEASE | A Phase 3, Randomized, Active-Controlled, Double-blind Clinical Study to Evaluate a Switch to Doravirine,Islatravir DOR, | 2020 |
| 2020-08-17 | Allergan, Inc. | $6,609 | Research payment | Cash or cash equivalent | A multicenter, randomized, double-blind, dose-conversion study to evaluate the safety and efficacy of HRT w Armour Thyro | 2020 | |
| 2020-08-17 | Allergan, Inc. | $5,966 | Research payment | Cash or cash equivalent | A multicenter, randomized, double-blind, dose-conversion study to evaluate the safety and efficacy of HRT w Armour Thyro | 2020 | |
| 2020-08-17 | Merck Sharp & Dohme LLC | $5,198 | Research payment | Cash or cash equivalent | MK-8591A Drug, INFECTIOUS DISEASE | A Phase 3, Randomized, Active-Controlled, Double-blind Clinical Study to Evaluate a Switch to Doravirine,Islatravir DOR, | 2020 |
| 2020-08-17 | Merck Sharp & Dohme LLC | $1,732 | Research payment | Cash or cash equivalent | MK-8591A Drug, INFECTIOUS DISEASE | A Phase 3, Randomized, Active-Controlled, Double-blind Clinical Study to Evaluate a Switch to Doravirine,Islatravir DOR, | 2020 |
| 2020-08-13 | Merck Sharp & Dohme LLC | $160 | Research payment | Cash or cash equivalent | V114 Biological, VACCINE | A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with R | 2020 |
| 2020-08-13 | Genentech, Inc. | $116 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | PH III OPEN LABEL STUDY ATEZO VS BSC FOLLOWING ADJUVANT CHEMO IN STAGE IB IIIA NSCLC | 2020 |
| 2020-08-11 | CSL Behring | $1,528 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-08-11 | Allergan, Inc. | $126 | Research payment | Cash or cash equivalent | BOTOX COSMETIC Biological | A Study Evaluating the Efficacy and Safety of BOTOX Intravesical Instillation in Patients with Overactive Bladder and Ur | 2020 |
| 2020-08-05 | Sterilmed, Inc. | $861 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-08-05 | Sterilmed, Inc. | $195 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-08-04 | Mallinckrodt Hospital Products Inc. | $2,022 | Research payment | Cash or cash equivalent | ACTHAR Biological, IMMUNOLOGY | A MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED PARALLEL GROUP, PILOT STUDY TO ASSESS THE EFFICACY AND SAFET | 2020 |
| 2020-08-04 | Eli Lilly and Company | $28 | Research payment | In-kind items and services | PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREA | 2020 | |
| 2020-08-03 | Genentech, Inc. | $8,343 | Research payment | Cash or cash equivalent | OCREVUS Biological, Immunology | ENSEMBLE | 2020 |
| 2020-08-03 | Medical Device Business Services, Inc. | $1,254 | Research payment | Cash or cash equivalent | Visitag Device, Cardiology | Evaluation of VISITAG SURPOINT Module with External Processing Unit (EPU) when used with the THERMOCOOL SMARTTOUCH SF an | 2020 |
| 2020-07-31 | SK Life Science, Inc. | $75 | Research payment | Cash or cash equivalent | YKP509C001 | 2020 | |
| 2020-07-30 | ABBVIE INC. | $2,624 | Research payment | Cash or cash equivalent | LUPRON DEPOT Drug, ENDOCRINOLOGY | M16-904 | 2020 |
| 2020-07-29 | Regeneron Pharmaceuticals, Inc. | $1,336 | Research payment | Cash or cash equivalent | PRALUENT Biological, CARDIOVASCULAR AND METABOLISM | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFECT OF PRALUENT ON NEUROCOGNITIVE FUNCTION IN PA | 2020 |
| 2020-07-29 | Regeneron Pharmaceuticals, Inc. | $396 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2020 |
| 2020-07-29 | Merck Sharp & Dohme LLC | $375 | Research payment | Cash or cash equivalent | V160 Biological, VACCINE | Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy | 2020 |
| 2020-07-29 | Regeneron Pharmaceuticals, Inc. | $200 | Research payment | Cash or cash equivalent | PRALUENT Biological, CARDIOVASCULAR AND METABOLISM | LONG TERM SAFETY STUDY OF PRALUENT IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA OR WITH NON-FAMILIAL HYPE | 2020 |
| 2020-07-28 | SANOFI PASTEUR INC. | $9,000 | Research payment | Cash or cash equivalent | PSK0008 Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine (PCV) when Administered Concomitantly with Routine | 2020 | |
| 2020-07-28 | SANOFI PASTEUR INC. | $3,000 | Research payment | Cash or cash equivalent | PSK0008 Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine (PCV) when Administered Concomitantly with Routine | 2020 | |
| 2020-07-28 | Merck Sharp & Dohme LLC | $1,427 | Research payment | Cash or cash equivalent | MK-1654 Drug, INFECTIOUS DISEASE | A Double-blind, Randomized, Placebo-controlled, Single Ascending Dose Trial to Evaluate the Safety, Tolerability, and Ph | 2020 |
| 2020-07-28 | ABBVIE INC. | $774 | Research payment | Cash or cash equivalent | LUPRON DEPOT Drug, ENDOCRINOLOGY | M16-904 | 2020 |
| 2020-07-27 | Artivion, Inc. | $11,000 | Research payment | Cash or cash equivalent | On-X Device, Cardiology and Vascular Diseases | On-X aortic prosthetic heart valve: Low dose warfarin post approval clinical registry | 2020 |
| 2020-07-27 | Gilead Sciences, Inc. | $1,250 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | The Simple Study in Coronavirus, Severe Subjects | 2020 |
| 2020-07-24 | Gilead Sciences, Inc. | $1,632 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | The Simple Study in Coronavirus, Severe Subjects | 2020 |
| 2020-07-23 | Merck Sharp & Dohme LLC | $6,343 | Research payment | Cash or cash equivalent | V114 Biological, VACCINE | A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerabilit | 2020 |
| 2020-07-23 | Merck Sharp & Dohme LLC | $4,896 | Research payment | Cash or cash equivalent | V114 Biological, VACCINE | A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerabilit | 2020 |
| 2020-07-22 | Gilead Sciences, Inc. | $54,376 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | The Simple Study in Coronavirus, Severe Subjects | 2020 |
| 2020-07-22 | Gilead Sciences, Inc. | $3,735 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | The Simple Study in Coronavirus, Severe Subjects | 2020 |
| 2020-07-22 | Gilead Sciences, Inc. | $3,558 | Research payment | Cash or cash equivalent | A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhib | 2020 | |
| 2020-07-22 | Gilead Sciences, Inc. | $2,581 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | The Simple Study - Subjects with Mild to Moderate Coronavirus Infection | 2020 |
| 2020-07-22 | Gilead Sciences, Inc. | $2,336 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | The Simple Study - Subjects with Mild to Moderate Coronavirus Infection | 2020 |
| 2020-07-22 | Merck Sharp & Dohme LLC | $225 | Research payment | Cash or cash equivalent | MK-8591A Drug, INFECTIOUS DISEASE | A Phase 3, Randomized, Active-Controlled, Double-blind Clinical Study to Evaluate a Switch to Doravirine,Islatravir DOR, | 2020 |
| 2020-07-21 | Merck Sharp & Dohme LLC | $6,416 | Research payment | Cash or cash equivalent | V114 Biological, VACCINE | A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with R | 2020 |
| 2020-07-20 | SK Life Science, Inc. | $1,399 | Research payment | Cash or cash equivalent | Cenobamate Drug, Neurology | YKP3089C033 | 2020 |
| 2020-07-15 | Allergan, Inc. | $4,465 | Research payment | Cash or cash equivalent | A multicenter, randomized, double-blind, dose-conversion study to evaluate the safety and efficacy of HRT w Armour Thyro | 2020 | |
| 2020-07-15 | Allergan, Inc. | $3,348 | Research payment | Cash or cash equivalent | A multicenter, randomized, double-blind, dose-conversion study to evaluate the safety and efficacy of HRT w Armour Thyro | 2020 | |
| 2020-07-15 | Allergan, Inc. | $2,408 | Research payment | Cash or cash equivalent | BOTOX COSMETIC Biological | A Study Evaluating the Efficacy and Safety of BOTOX Intravesical Instillation in Patients with Overactive Bladder and Ur | 2020 |
| 2020-07-09 | Janssen Research & Development, LLC | $13,823 | Research payment | Cash or cash equivalent | A multi-center, double-blind, placebo-controlled Phase 2b study to evaluate the efficacy and safety 01F macitentan in su | 2020 | |
| 2020-07-09 | PFIZER INC. | $967 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2020 | |
| 2020-07-08 | Merck Sharp & Dohme LLC | $1,509 | Research payment | Cash or cash equivalent | MK-7264 Drug, RESPIRATORY | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-Month Study to Evaluate the Efficacy and Safety of MK-7264 i | 2020 |
| 2020-07-08 | W. L. Gore & Associates, Inc. | $782 | Education | Cash or cash equivalent | EXCLUDER AAA Endoprosthesis Device, Devices | 2020 | |
| 2020-07-02 | F. Hoffmann-La Roche AG | $4,614 | Research payment | Cash or cash equivalent | OCREVUS Biological, Immunology | OCRELIZUMAB IN PATIENTS WITH RMS | 2020 |
| 2020-07-02 | F. Hoffmann-La Roche AG | $2,958 | Research payment | Cash or cash equivalent | OCREVUS Biological, Immunology | OCRELIZUMAB IN PATIENTS WITH RMS | 2020 |
| 2020-07-01 | Genentech, Inc. | $12,750 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHII IL22FC ANTI ST2 IN SEVERE COVID 19 PNEUMONIA | 2020 |
| 2020-07-01 | Roche Products Limited | $3,000 | Research payment | Cash or cash equivalent | OCREVUS Biological, Immunology | OBSERVATIONAL STUDY OF OCRELIZUMAB TREATED MULTIPLE SCLEROSIS PATIENTS US COMMITMENT | 2020 |
| 2020-07-01 | Genentech, Inc. | $2,500 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHII IL22FC ANTI ST2 IN SEVERE COVID 19 PNEUMONIA | 2020 |
| 2020-06-30 | ABBVIE INC. | $7,859 | Research payment | Cash or cash equivalent | LUPRON DEPOT Drug, ENDOCRINOLOGY | M16-904 | 2020 |
| 2020-06-26 | Merck Sharp & Dohme LLC | $31,151 | Research payment | Cash or cash equivalent | MK-7264 Drug, RESPIRATORY | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-Month Study to Evaluate the Efficacy and Safety of MK-7264 i | 2020 |
| 2020-06-25 | Merck Sharp & Dohme LLC | $5,561 | Research payment | Cash or cash equivalent | V114 Biological, VACCINE | A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerabilit | 2020 |
The latest 200 records of 433.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Tacoma, WA, county Pierce County, WA, state Washington; placed by its city name.
| Measure | Place (city or town) Tacoma, WA | County Pierce County, WA | State Washington |
|---|---|---|---|
| Population B01003 | 222,758 | 930,319 | 7,816,116 |
| Population, 2020 census P1 | 219,346 | 921,130 | 7,705,281 |
| Median age B01002 | 37.2 | 37.0 | 38.3 |
| Under 18 B01001 | 19.8% | 23.0% | 21.4% |
| 65 and over B01001 | 15.0% | 14.8% | 16.6% |
| Households B11001 | 93,033 | 351,330 | 3,064,820 |
| Foreign born B05002 | 12.6% | 10.9% | 15.4% |
| Median household income B19013 | $85,884 | $99,564 | $98,141 |
| Median family income B19113 | $103,940 | $114,873 | $118,075 |
| Per capita income B19301 | $45,650 | $47,648 | $53,744 |
| Poverty rate B17001 | 12.4% | 8.8% | 9.9% |
| Unemployment rate B23025 | 5.6% | 5.2% | 5.1% |
| Civilian labor force B23025 | 118,971 | 465,747 | 4,024,423 |
| Mean commute (minutes) B08013 | 28.8 | 31.3 | 26.6 |
| Bachelor's degree or higher B15003 | 34.5% | 30.9% | 39.6% |
| Housing units B25001 | 97,298 | 369,709 | 3,306,620 |
| Owner-occupied B25003 | 55.8% | 64.7% | 63.8% |
| Renters B25003 | 44.2% | 35.3% | 36.2% |
| Median home value B25077 | $479,600 | $526,600 | $564,600 |
| Median gross rent B25064 | $1,676 | $1,806 | $1,760 |
| White, not Hispanic B03002 | 55.6% | 61.4% | 63.1% |
| Black B03002 | 9.3% | 7.0% | 3.8% |
| Hispanic or Latino B03002 | 13.8% | 12.8% | 14.4% |
| Asian B03002 | 9.4% | 6.8% | 9.7% |
| American Indian and Alaska Native B03002 | 0.8% | 0.6% | 0.8% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Tacoma, WA.
Comments